Glenmede Trust’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Glenmede Trust’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-8,262	Closed	-$41	–	3192
2019 Q3	$41	Sell	8,262 -438	-5%	-$2.18K	﹤0.01%	1754
2019 Q2	$53	Hold	8,700	–	–	﹤0.01%	1652
2019 Q1	$40	Hold	8,700	–	–	﹤0.01%	1785
2018 Q4	$36	Buy	+8,700	New	+$44.3K	﹤0.01%	1737
2018 Q2	–	Sell	-358	Closed	-$2K	–	2445
2018 Q1	$2K	Hold	358	–	–	﹤0.01%	2628
2017 Q4	$2K	Buy	+358	New	+$2.17K	﹤0.01%	2628
2017 Q3	–	Sell	-33,907	Closed	-$320K	–	2896
2017 Q2	$320K	Hold	33,907	–	–	﹤0.01%	1055
2017 Q1	$320K	Hold	33,907	–	–	﹤0.01%	1055
2016 Q4	$292K	Buy	+33,907	New	+$251K	﹤0.01%	1104
2014 Q2	–	Sell	-81,662	Closed	-$333K	–	2412
2014 Q1	$333K	Buy	81,662 +47,194	+137%	+$241K	﹤0.01%	1010
2013 Q4	$183K	Hold	34,468	–	–	﹤0.01%	1182
2013 Q3	$173K	Hold	34,468	–	–	﹤0.01%	1185
2013 Q2	$153K	Buy	+34,468	New	+$155K	﹤0.01%	1175

Other funds holding PGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Glenmede Trust's PGNX Position: Q4 2019 in Review

Glenmede Trust sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2019, closing a stake of 8,262 shares — an estimated $41 sold.

Glenmede Trust first reported a position in PGNX in Q2 2013 and held it in 13 quarters. The position peaked at $333K in Q1 2014. 128 funds tracked by Wall St. Rank hold PGNX as of Q4 2019.

Glenmede Trust reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2019 after selling out during the quarter.
Glenmede Trust sold 8,262 Progenics Pharmaceuticals Inc shares in Q4 2019, an estimated $41.
Glenmede Trust first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 13 quarters.
Glenmede Trust's Progenics Pharmaceuticals Inc position peaked at $333K in Q1 2014.
128 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2019.

Based on Glenmede Trust's 13F filing for Q4 2019, filed 12 Feb 2020.